Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose

Platelet recovery after allogeneic haemopoietic stem cell transplant (HSCT) and predictive factors were analysed in 342 patients with haematological malignancies. All patients were prepared with cyclophosphamide plus total body irradiation, and received an unmanipulated HSCT from an HLA‐identical si...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2001-01, Vol.112 (1), p.219-227
Main Authors: Dominietto, Alida, Raiola, Anna Maria, Van Lint, Maria Teresa, Lamparelli, Teresa, Gualandi, Francesca, Berisso, Giovanni, Bregante, Stefania, Frassoni, Francesco, Casarino, Lucia, Verdiani, Simonetta, Bacigalupo, Andrea
Format: Article
Language:English
Subjects:
Adolescent
Adult
allogeneic bone marrow transplantation
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Bone Marrow Transplantation - mortality
Bone marrow, stem cells transplantation. Graft versus host reaction
Child
Chimera
Cytomegalovirus Infections - complications
Female
Graft vs Host Disease
graft‐versus‐host disease
haematopoietic recovery
Hematologic Neoplasms - blood
Hematologic Neoplasms - mortality
Hematologic Neoplasms - surgery
Hematology
Hematopoietic Stem Cell Transplantation - mortality
Histocompatibility Testing
Humans
Male
Medical sciences
Middle Aged
Platelet Count
Prognosis
Thrombocytopenia - complications
Time Factors
Tissue Donors
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplantation, Homologous
Twins, Monozygotic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platelet recovery after allogeneic haemopoietic stem cell transplant (HSCT) and predictive factors were analysed in 342 patients with haematological malignancies. All patients were prepared with cyclophosphamide plus total body irradiation, and received an unmanipulated HSCT from an HLA‐identical sibling (n = 270), a matched unrelated donor (n = 67) or an identical twin (n = 5). The source of stem cells was peripheral blood (n = 15) or bone marrow (n = 327). Graft‐vs.‐host disease (GvHD) prophylaxis consisted of cyclosporin A with or without methotrexate. The proportion of patients with
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.2001.02468.x